149 related articles for article (PubMed ID: 36211404)
1. Reaction of SARS-CoV-2 antibodies with other pathogens, vaccines, and food antigens.
Vojdani A; Vojdani E; Melgar AL; Redd J
Front Immunol; 2022; 13():1003094. PubMed ID: 36211404
[TBL] [Abstract][Full Text] [Related]
2. Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases.
Vojdani A; Vojdani E; Kharrazian D
Front Immunol; 2020; 11():617089. PubMed ID: 33584709
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
Elife; 2022 Jan; 11():. PubMed ID: 35072628
[TBL] [Abstract][Full Text] [Related]
4. Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease.
Deschambault Y; Lynch J; Warner B; Tierney K; Huynh D; Vendramelli R; Tailor N; Frost K; Sajesh B; LeBlanc K; Layne C; Lin L; Tamming L; Beniac D; Booth S; Carpenter M; Safronetz D; Li X; Kobasa D; Cao J
J Virol; 2022 May; 96(9):e0038922. PubMed ID: 35412347
[TBL] [Abstract][Full Text] [Related]
5. The Immune Response to SARS-CoV-2 Vaccination: Insights Learned From Adult Patients With Common Variable Immune Deficiency.
Quinti I; Locatelli F; Carsetti R
Front Immunol; 2021; 12():815404. PubMed ID: 35126372
[TBL] [Abstract][Full Text] [Related]
6. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
7. Microfluidic Antibody Affinity Profiling Reveals the Role of Memory Reactivation and Cross-Reactivity in the Defense Against SARS-CoV-2.
Denninger V; Xu CK; Meisl G; Morgunov AS; Fiedler S; Ilsley A; Emmenegger M; Malik AY; Piziorska MA; Schneider MM; Devenish SRA; Kosmoliaptsis V; Aguzzi A; Fiegler H; Knowles TPJ
ACS Infect Dis; 2022 Apr; 8(4):790-799. PubMed ID: 35352558
[TBL] [Abstract][Full Text] [Related]
8. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
[TBL] [Abstract][Full Text] [Related]
9. Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants.
Kingstad-Bakke B; Lee W; Chandrasekar SS; Gasper DJ; Salas-Quinchucua C; Cleven T; Sullivan JA; Talaat A; Osorio JE; Suresh M
Proc Natl Acad Sci U S A; 2022 May; 119(20):e2118312119. PubMed ID: 35561224
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
11. Cross-reactive antibodies elicited to conserved epitopes on SARS-CoV-2 spike protein after infection and vaccination.
Geanes ES; LeMaster C; Fraley ER; Khanal S; McLennan R; Grundberg E; Selvarangan R; Bradley T
Sci Rep; 2022 Apr; 12(1):6496. PubMed ID: 35444221
[TBL] [Abstract][Full Text] [Related]
12. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
[TBL] [Abstract][Full Text] [Related]
13. A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine.
Jangra S; Landers JJ; Rathnasinghe R; O'Konek JJ; Janczak KW; Cascalho M; Kennedy AA; Tai AW; Baker JR; Schotsaert M; Wong PT
Front Immunol; 2021; 12():729189. PubMed ID: 34603303
[TBL] [Abstract][Full Text] [Related]
14. Cross-Recognition of SARS-CoV-2 B-Cell Epitopes with Other Betacoronavirus Nucleoproteins.
Tajuelo A; López-Siles M; Más V; Pérez-Romero P; Aguado JM; Briz V; McConnell MJ; Martín-Galiano AJ; López D
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328398
[TBL] [Abstract][Full Text] [Related]
15. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
16. Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray.
Camerini D; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Shandling A; Huynh V; Teng AA; Hermanson G; Pablo JV; Stumpf MM; Lester SN; Harcourt J; Tamin A; Rasheed M; Thornburg NJ; Satheshkumar PS; Liang X; Kennedy RB; Yee A; Townsend M; Campo JJ
Microbiol Spectr; 2021 Oct; 9(2):e0141621. PubMed ID: 34704808
[TBL] [Abstract][Full Text] [Related]
17. Antibody and Memory B-Cell Immunity in a Heterogeneously SARS-CoV-2-Infected and -Vaccinated Population.
Bednarski E; Del Rio Estrada PM; DaSilva J; Boukadida C; Zhang F; Luna-Villalobos YA; Rodríguez-Rangel X; Pitén-Isidro E; Luna-García E; Díaz Rivera D; López-Sánchez DM; Tapia-Trejo D; Soto-Nava M; Astorga-Castañeda M; Martínez-Moreno JO; Urbina-Granados GS; Jiménez-Jacinto JA; Serna Alvarado FJ; Enriquez-López YE; López-Arellano O; Reyes-Teran G; Bieniasz PD; Avila-Rios S; Hatziioannou T
mBio; 2022 Aug; 13(4):e0084022. PubMed ID: 35735743
[TBL] [Abstract][Full Text] [Related]
18. The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice.
Hu L; Xu Y; Wu L; Feng J; Zhang L; Tang Y; Zhao X; Mai R; Chen L; Mei L; Tan Y; Du Y; Zhen Y; Su W; Peng T
Viruses; 2022 Apr; 14(5):. PubMed ID: 35632595
[TBL] [Abstract][Full Text] [Related]
19. Strong homology between SARS-CoV-2 envelope protein and a Mycobacterium sp. antigen allows rapid diagnosis of Mycobacterial infections and may provide specific anti-SARS-CoV-2 immunity via the BCG vaccine.
Nuovo G; Tili E; Suster D; Matys E; Hupp L; Magro C
Ann Diagn Pathol; 2020 Oct; 48():151600. PubMed ID: 32805515
[TBL] [Abstract][Full Text] [Related]
20. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]